Mucinous borderline ovarian tumors with BRAF V600E mutation may have low risk for progression to invasive carcinomas
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1432-0711
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Mucinous borderline ovarian tumors with BRAF V600E mutation may have low risk for progression to invasive carcinomas ; volume:302 ; number:2 ; day:16 ; month:6 ; year:2020 ; pages:487-495 ; date:8.2020
Archives of gynecology and obstetrics ; 302, Heft 2 (16.6.2020), 487-495, 8.2020
- Urheber
-
Ohnishi, Kaori
Nakayama, Kentaro
Ishikawa, Masako
Ishibashi, Tomoka
Yamashita, Hitomi
Nakamura, Kohei
Minamoto, Toshiko
Iida, Kouji
Razia, Sultana
Ishikawa, Noriyoshi
Kyo, Satoru
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s00404-020-05638-8
- URN
-
urn:nbn:de:101:1-2020082323323720545913
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:58 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Ohnishi, Kaori
- Nakayama, Kentaro
- Ishikawa, Masako
- Ishibashi, Tomoka
- Yamashita, Hitomi
- Nakamura, Kohei
- Minamoto, Toshiko
- Iida, Kouji
- Razia, Sultana
- Ishikawa, Noriyoshi
- Kyo, Satoru
- SpringerLink (Online service)
Ähnliche Objekte (12)
BRAF V600E mutation is associated with aggressive features in papillary thyroid carcinomas ≤ 1.5 cm
Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
Colorectal carcinomas with mucinous differentiation are associated with high frequent mutation of KRAS or BRAF mutations, irrespective of quantity of mucinous component
Validierung eines Protokolls zur manuellen, mutationsspezifischen BRAF V600E Immunhistochemie
Loss of Phd2 cooperates with BRAF V600E to drive melanomagenesis
A novel algorithm for better distinction of primary mucinous ovarian carcinomas and mucinous carcinomas metastatic to the ovary
BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature
BCL-XL inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAF V600E colorectal cancer
Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy
RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAF V600E metastatic colorectal cancer
Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer
Frequency of BRAF V600E mutations in 969 central nervous system neoplasms
BRAF V600E mutation is associated with aggressive features in papillary thyroid carcinomas ≤ 1.5 cm
Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
Colorectal carcinomas with mucinous differentiation are associated with high frequent mutation of KRAS or BRAF mutations, irrespective of quantity of mucinous component
Validierung eines Protokolls zur manuellen, mutationsspezifischen BRAF V600E Immunhistochemie
Loss of Phd2 cooperates with BRAF V600E to drive melanomagenesis
A novel algorithm for better distinction of primary mucinous ovarian carcinomas and mucinous carcinomas metastatic to the ovary
BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature
BCL-XL inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAF V600E colorectal cancer
Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy
RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAF V600E metastatic colorectal cancer
Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer
Frequency of BRAF V600E mutations in 969 central nervous system neoplasms
BRAF V600E mutation is associated with aggressive features in papillary thyroid carcinomas ≤ 1.5 cm
Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
Colorectal carcinomas with mucinous differentiation are associated with high frequent mutation of KRAS or BRAF mutations, irrespective of quantity of mucinous component
Validierung eines Protokolls zur manuellen, mutationsspezifischen BRAF V600E Immunhistochemie
Loss of Phd2 cooperates with BRAF V600E to drive melanomagenesis
A novel algorithm for better distinction of primary mucinous ovarian carcinomas and mucinous carcinomas metastatic to the ovary
BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature
BCL-XL inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAF V600E colorectal cancer
Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy
RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAF V600E metastatic colorectal cancer
Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer